CCWM
IMDX

Cassaday & Co Wealth Management’s Insight Molecular Diagnostics IMDX Stock Holding History

Cassaday & Co Wealth Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36 Sell
6
-4
-40% -$20 ﹤0.01% 1302
2026
Q1 		$33 Buy
+10
New +$58 ﹤0.01% 1354

Other funds holding IMDX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
FOR
Family Office Research Bethesda, Maryland $267M AUM 27.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Cassaday & Co Wealth Management's IMDX Position: Q2 2026 in Review

Cassaday & Co Wealth Management reduced its Insight Molecular Diagnostics (IMDX) stake by 40% in Q2 2026, selling an estimated $20 and leaving 6 shares worth $36. The position accounts for ﹤0.01% of the portfolio, ranked #1302.

Cassaday & Co Wealth Management first reported a position in IMDX in Q1 2026 and has held it in 2 quarters since. 40 funds tracked by Wall St. Rank hold IMDX as of Q2 2026.

  • Cassaday & Co Wealth Management held 6 shares of Insight Molecular Diagnostics worth $36 as of Q2 2026.
  • Cassaday & Co Wealth Management sold 4 Insight Molecular Diagnostics shares in Q2 2026, an estimated $20.
  • Insight Molecular Diagnostics made up ﹤0.01% of Cassaday & Co Wealth Management's portfolio in Q2 2026, its #1302 holding.
  • Cassaday & Co Wealth Management first reported a position in Insight Molecular Diagnostics in Q1 2026 and has held it in 2 quarters since.
  • 40 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.